Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr82.75 SEK
Change Today +1.00 / 1.22%
Volume 79.4K
MVIRB On Other Exchanges
As of 11:30 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/14 - kr140.93
52 Week Low
03/30/15 - kr75.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based pharmaceutical company, develops and sells pharmaceuticals for the treatment of infectious diseases, osteoarthritis, neuropathic pain, and oncology in the Nordic region. It focuses on the research and development of pharmaceuticals primarily in the hepatitis C area; osteoarthritis; neuropathic pain; respiratory syncytial virus; and HIV/AIDS. The company sells 16 prescription pharmaceuticals under various brands, including Mollipect, Citodon, Digoxin BioPhausia, Egazil, Laxabon, Lithionit, Morfin Special, Nitroglycerin BioPhausia, Paraflex, Probecid, Solvezink, Suscard, Teovent, and Theo-Dur. It has a collaboration agreement with Cancer Research Technology to develop cancer drugs. Medivir AB is headquartered in Stockholm, Sweden.

138 Employees
Last Reported Date: 05/5/15

medivir ab-b shs (MVIRB) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr1.9M
Compensation as of Fiscal Year 2014.

medivir ab-b shs (MVIRB) Key Developments

Medivir Aktiebolag Announces Election of Board of Directors

Medivir Aktiebolag announced that at the annual general meeting held on May 5, 2015 elected Johan Harmenberg and Helena Levander as new board members.

Medivir AB Reports Consolidated and Parent Company Earnings Results for the First Quarter Ended March 31, 2015

Medivir AB reported consolidated and parent company earnings results for the first quarter ended March 31, 2015. For the quarter, on consolidated basis, reported net turnover of SEK 215.9 million compared to SEK 208.2 million a year ago. Operating profit was SEK 76.2 million compared to SEK 88.6 million a year ago. Profit after financial items was SEK 82.9 million compared to SEK 90.3 million a year ago. Net profit for the period attributable to parent company shareholders was SEK 66.7 million compared to SEK 283.8 million a year ago. Diluted earnings per share were SEK 2.27 compared to SEK 9.01 a year ago. Cash flow from operating activities was SEK 205.3 million compared to cash flow used in operating activities of SEK 57.8 million a year ago. Acquisition of fixed assets was SEK 4.0 million compared to SEK 5.2 million a year ago. Return on shareholders' equity was 4.8% compared to 9.1% a year ago. Return on capital employed was 4.8% compared to 8.8% a year ago. EBITDA was SEK 84.6 million compared to SEK 96.7 million a year ago. EBIT was SEK 76.2 million compared to SEK 88.6 million a year ago. For the quarter, on parent company basis, reported net turnover of SEK 169.8 million compared to SEK 169.8 million a year ago. Operating profit was SEK 61.1 million compared to SEK 73.7 million a year ago. Profit after financial items was SEK 68.6 million compared to SEK 75.5 million a year ago. Net profit was SEK 53.5 million compared to SEK 272.3 million a year ago.

Medivir AB Announces Positive Preclinical Antiviral and Safety Profile of MIV-802

Medivir AB announced that the preclinical antiviral and safety profile of MIV-802, Medivir's nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus (HCV) infection, was presented at The International Liver CongressTM 2015 of the European Association for the Study of the Liver (EASL), taking place in Vienna from April 22-26. The presentation, entitled 'Preclinical characterization of MIV-802, a novel uridine nucleotide HCV NS5B polymerase inhibitor, for treatment of hepatitis C virus infection' (Abstract P0688), outlines the favourable preclinical profile of MIV-802. This includes selective inhibition of the HCV NS5B polymerase by the active metabolite of MIV-802 when compared with several human DNA and RNA polymerases, the potent and selective pan-genotypic inhibition of HCV RNA replication by MIV-802 in vitro, and its low toxicity in a range of in vitro and in vivo studies. The presentation also describes preclinical studies that show the selective delivery of high levels of the active metabolite of MIV-802 to the liver. The data therefore support the continuing development of MIV-802 for the future treatment of HCV infection in combination with other Direct Acting Antivirals (DAAs).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr82.75 SEK +1.00

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies

Industry Analysis


Industry Average

Valuation MVIRB Industry Range
Price/Earnings 2.8x
Price/Sales 1.4x
Price/Book 1.6x
Price/Cash Flow 2.4x
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at